The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.

By H. Maeda, Hideaki Nakamura, Jun Fang. Advanced Drug Delivery Reviews, 2013

2,165 citations recorded by the source corpus.

Subfields: Biomaterials, Biophysics, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/663fbfdfbf8b466f77e00c9b4740547f38010296

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. N. Bertrand
2. Xiaoyang Xu
3. O. Farokhzad
4. R. Juliano
5. Peter L. Choyke
6. Hisataka Kobayashi
7. S. Hua
8. R. Watanabe

In Biophysics

1. Xueqing Zhang
2. G. Storm

In Materials Chemistry

1. R. Juliano
2. O. Farokhzad
3. M. Ernsting
4. Shyh-Dar Li
5. Aniruddha Roy
6. G. Storm
7. M. Murakami

Citations in the corpus

• Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. (2013, methodology): “The earliest example was generated by the Maeda group [2, 61-63] : a styrene maleic anhydride polymer was conjugated to neocarzinostatin (SMANCS), and patients treated with this therapeutic were imaged by CT, with tumor accumulation of the therapy reading 10-200 times higher than normal tissues.”
• Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “reduction in collagen expression), which leads to vessel decompression and to enhanced EPR [12, 56].”
• The delivery of therapeutic oligonucleotides (2016, background): “The concept is that the increased leakiness of tumor vasculature will allow nanoparticles to selectively accumulate at these sites (51).”
• Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions (2017, background): “This phenomenon is called the Enhanced Permeability and Retention (EPR) effect and is often utilized in cancer therapeutics [42].”
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “The EPR effect was first observed in 1986 (Matsumura and Maeda, 1986) and has since been exploited particularly for the development of NNMs for passive tumor targeting, leading to NNMs with adequate physicochemical properties and prolonged circulation half-life that accumulate in tumors over time (M”